Sanofi completed the acquisition of Vigil Neuroscience on August 6, 2025. The acquisition strengthens Sanofi’s neurology pipeline with VG-3927, a novel TREM2 agonist aimed at treating Alzheimer’s disease. This acquisition, valued at approximately $470 million, is not expected to impact Sanofi’s financial guidance for 2025 and marks a strategic move to strengthen its research in neurodegenerative diseases.

Sanofi is a research and development-driven, AI-powered biopharmaceutical company focused on improving lives through innovative medicines and vaccines. The company leverages its deep understanding of the immune system to develop treatments that address urgent healthcare, environmental, and societal challenges globally. Sanofi is listed on EURONEXT and NASDAQ.

Sanofi Finalizes Acquisition of Vigil Neuroscience to Boost Neurology Pipeline

Sanofi completed the acquisition of Vigil Neuroscience for approximately $470 million to strengthen its neurology pipeline, specifically targeting Alzheimer’s disease with the drug VG-3927. The acquisition, valued at $470 million, is a strategic move to enhance research in neurodegenerative diseases and does not impact Sanofi’s 2025 financial guidance.